Anaïs Barut is the CEO and co-founder of DAMAE Medical, a MedTech start-up based in Paris. Anaïs and her team have successfully built a handheld probe that can detect whether skin moles are cancerous or benign. It does this by using a computational algorithm which allows the reconstruction of an image of the tissue from the measured optical signal.
Founded in 2014, DAMAE aims to revolutionise the way the world’s most common cancer is identified. DAMAE will use biophotonics — science using light to analyse the structure of biological objects — to transform medical diagnostic procedures. The device, which is called OCTAV, is non-invasive and based on pioneering optical technology.
In May 2017, the company announced a €2 million investment round with multiple VC firms and private investors. That year also saw the company being granted an ISO 13495 from GMED certification pertaining to the design of medical imaging devices for cutaneous cancer diagnostic aid in dermatology.
Anaïs has previously worked as an assistant engineer at EDF. She holds a master’s in engineering from the Institut d’Optique and an MBA in entrepreneurship from HEC Paris. She was listed on Forbes’ 30 Under 30 European Healthcare and Science category in 2018.